Iberdomide clinical trials
Iberdomide is named as an intervention in 20 current clinical trials in our USA, Israel, Spain, Australia, France, Canada, Netherlands, UK, Germany, Italy, Japan, Poland, South Korea, Austria, Norway, Taiwan, India, China, Belgium, Sweden, Denmark, Czechia, Portugal, Turkey, Brazil, Mexico, Ireland, Switzerland and Singapore registers. 8 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Celgene (3). The most-studied condition is Multiple Myeloma.
Where Iberdomide is approved
All regulators →Of the three regulators tracked here, the first to approve Iberdomide was the US, on 13 Aug 2026.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Iberdomide patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Iberdomide, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 7 listed patents; the last listed expires 30 Sep 2039 (US 11529339).
- Latest patent on the drug substance itself: 25 Sep 2033 (US 9221788).
- Exclusivity NCE: New chemical entity, until 13 Aug 2031.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
How Iberdomide works
All drug targets →- CRL4(CRBN) E3 ubiquitin ligase modulator ModulatorTarget: CRL4(CRBN) E3 ubiquitin ligase✓ In ChEMBL and the Guide to Pharmacology
- Plasma cell myelomaPhase 3
- SarcoidosisPhase 2
- Skin sarcoidosisPhase 2
- Smoldering plasma cell myelomaPhase 2
- Systemic lupus erythematosusPhase 2
- NeuroblastomaPhase 1/2
- Non-Hodgkin lymphomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3989927, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9618, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Iberdomide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Iberdomide
20 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Iberdomide
7 conditionsSponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Iberdomide trials
How many clinical trials are testing Iberdomide?
20 current trials in our USA, Israel, Spain, Australia, France, Canada, Netherlands, UK, Germany, Italy, Japan, Poland, South Korea, Austria, Norway, Taiwan, India, China, Belgium, Sweden, Denmark, Czechia, Portugal, Turkey, Brazil, Mexico, Ireland, Switzerland and Singapore registers name Iberdomide (also registered as CC-220) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Iberdomide trials recruiting patients?
Yes. 8 of the 20 trials are recruiting: 3 with sites in USA, 4 with sites in Israel, 2 with sites in Spain, 3 with sites in Australia, 2 with sites in France, 3 with sites in Canada, 1 with sites in Netherlands, 1 with sites in UK, 1 with sites in Germany, 2 with sites in Japan, 1 with sites in Poland, 1 with sites in South Korea and 2 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Iberdomide clinical trials?
Celgene (3), AbbVie (2), Hoffmann-La Roche (2) and PETHEMA Foundation (2), among 14 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Iberdomide clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Iberdomide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Iberdomide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Iberdomide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.